Key terms
About KNSA
Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, Vixarelimab, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Lexington, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest KNSA news
Today
11:05am ET
Buy Rating Affirmed for Kiniksa Pharmaceuticals Amidst Growth Potential and Strong Commercial Execution
Apr 02
2:55pm ET
Kiniksa Pharmaceuticals (KNSA) Receives a Buy from Goldman Sachs
Apr 02
7:46am ET
Kiniksa announces development indication for abiprubart
Apr 02
7:42am ET
Kiniksa Pharmaceuticals Advances Clinical Trials and Ensures Positive Cash Flow
Feb 28
12:00pm ET
Analysts Are Bullish on These Healthcare Stocks: G1 Therapeutics (GTHX), Kiniksa Pharmaceuticals (KNSA)
Feb 28
7:32am ET
Kiniksa reports Q4 EPS 35c, consensus (14c)
No recent press releases are available for KNSA
KNSA Financials
Key terms
Ad Feedback
KNSA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
KNSA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range